References
- Pruna A, Metivier F, Akposso K, Saltiel C, Bedrossian J, Idatte J M, Nochy D, Druet P. Pefloxacine as first-line treatment in nephrotic syndrome. Lancet 1992; 340: 828–829
- Geffriaud-Ricouard C, Jungers P, Chauveau D, Grunfeld JP. Inefficiency and toxicity of pefloxacine in focal and segmental glomerulosclerosis with steroid-resistant nephrotic syndrome. Lancet 1993; 341: 1475
- Aigrain E J, Brun P, Bennasr S, Loirat C. Side-effects of pefloxacine in idiopathic nephrotic syndrome. Lancet 1993; 342: 438–439
- Ginsburg C, Toledano D, Deray G, Vlassopoulos D, Baumelou A, Jacobs C. Pefloxacin as first-line treatment in nephrotic syndrome. Nephrol Dial Transplant 1994; 9: 335
- Wang Z, Wang Z G, Liu Z. Changes in glomerular fixed anionic charge sites in adriamycin nephrosis in rats. Chin Med J 1991; 104: 128–131
- Okasora T, Takikawa T, Utsunomiya Y, Senoh I, Hayashibara H, Shiraki K, Kasagi T, Shimizu F. Suppressive effect of superoxide dismutase on adriamycine nephropathy. Nephron 1992; 60: 199–203
- Korzets Z, Pomeranz A, Golan E, Green J, Bernheim J. Antiproteinuric effect of pefloxacin (P) in adriamycin (A) induced nephrotic syndrome (NS) in rats. Abstract Book of the XXXIst Congress of the ERA/EDTA. Vienna 1994; 46
- Hinoshita F, Noma T, Tomura S, Shugai T, Yata J. Decreased production and responsiveness of interleukin 2 in lymphocytes of patients with nephrotic syndrome. Nephron 1990; 54: 122–126
- Heslan J M, Branellec A I, Pilatte Y, Lang P, Lagrue G. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 1991; 86: 157–162
- Riensbeck K, Andersson J, Gullberg M, Forsgren A. Fluorinated 4-quinolones induce hyperproduction of interleukin 2. Proc Natl Acad Sci USA 1989; 86: 2809–2813
- Couser WG. Pathogenesis of glomerulonephritis. Kidney Int 1993; 44: S19–S26, Suppl 42